The Lyme Disease Diagnostic Market Size is substantial globally, estimated to be valued between $1.5 Billion and $2.5 Billion in 2023/2024, and projected to reach up to $4.5 Billion or more by the early 2030s, growing at a CAGR typically ranging from 5.0% to 8.5%. This significant valuation is directly driven by the high volume of tests performed annually (millions worldwide), which includes the mandatory TTT algorithm requiring two tests per patient, compounded by testing for suspected co-infections and follow-up tests for persistent symptoms.

In projecting future value, there is little bit change in content from now. The expansion of the Lyme Disease Diagnostic Market Size is underpinned by two factors: high disease incidence and the premium pricing of next-generation assays. While serological tests are relatively inexpensive, the rapid shift towards high-value molecular diagnostics (PCR) and advanced T-cell assays (IGRA) dramatically increases the average cost per test, directly inflating the overall market size. Moreover, the increasing adoption of automated diagnostic platforms by large laboratories requires significant capital investment, further contributing to the total market valuation and growth trajectory. [Lyme Disease Diagnostic Market Size]